Business
Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA®(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Re...
About this update from Vortex Energy Corp.
[{"type":"text","content":"\n \n \n \n Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA®(elexacaftor/tezacaftor/ivacaftor and ivacaftor)\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n TORONTO\n \n ,\n \n Sept. 17, 2021\n \n /CNW/ -\n \n Vertex Pharmaceuticals Incorporated\n \n (\n \n Canada\n \n ) (Nasdaq: VRTX) today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle regarding the public reimbursement of\n \n Pr\n \n TRIKAFTA\n \n ®\n \n (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for eligible patients with cystic fibrosis (CF).\n \n \n \n \n \n \n \n \n \n This is an extension of the LOI with the pCPA including\n \n Pr\n \n KALYDECO\n \n ®\n \n (ivacaftor) and\n \n Pr\n \n ORKAMBI\n \n ®\n \n (lumacaftor/ivacaftor).\n \n \n \"This is a significant milestone for patients with CF in\n \n Canada\n \n ,\" said\n \n Duncan McKechnie\n \n , Senior Vice President, North America Commercial Operations, Vertex Pharmaceuticals. \"We would like to thank the pCPA and the participating jurisdictions for their collaborative approach. We share the urgency of the CF community to bring this process to a successful conclusion, and we will continue our work with all the provinces and territories so that eligible people with CF have the opportunity to receive TRIKAFTA, KALYDECO and ORKAMBI.\"\n \n \n This extension of the LOI follows the positive clinical recommendation for TRIKAFTA\n \n ®\n \n by both the Canadian Agency for Drugs and Technology in Health (CADTH) and l'Institut national d'excellence en santé et en services sociaux (INESSS) in\n \n Quebec\n \n .\n \n \n \n About TRIKAFTA\n \n ®\n \n \n \n \n TRIKAFTA\n \n ®\n \n (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the\n \n F508del...